Incentives for Drug Development — The Curious Case of Colchicine
Authors:
- Aaron S. KesselheimAKAaron S. Kesselheim
- Daniel H. SolomonDSDaniel H. Solomon
- 3 June 2010
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 362 (22) , 2045-2047
Abstract
In July 2009, the Food and Drug Administration (FDA) officially announced what physicians have long known — that the drug colchicine can effectively treat acute flares of gouty arthritis. The plant from which colchicine is derived was first used as a therapeutic agent for gout more than 3000 years ago in ancient Greece, and the tablet form has been widely available as a generic prescription drug in the United States since the 19th century. On the basis of evidence that had built up over the years, numerous consensus guidelines recommended colchicine as an effective second-line treatment for gout — for example, in patients who had adverse effects from nonsteroidal antiinflammatory drugs.1Keywords
This publication has 3 references indexed in Scilit:
- High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine studyArthritis & Rheumatism, 2010
- EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 2006
- DOES COLCHICINE WORK? THE RESULTS OF THE FIRST CONTROLLED STUDY IN ACUTE GOUTAustralian and New Zealand Journal of Medicine, 1987